BRPI0312649A2 - compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos. - Google Patents

compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.

Info

Publication number
BRPI0312649A2
BRPI0312649A2 BRPI0312649A BR0312649A BRPI0312649A2 BR PI0312649 A2 BRPI0312649 A2 BR PI0312649A2 BR PI0312649 A BRPI0312649 A BR PI0312649A BR 0312649 A BR0312649 A BR 0312649A BR PI0312649 A2 BRPI0312649 A2 BR PI0312649A2
Authority
BR
Brazil
Prior art keywords
compounds
processes
pharmaceutical compositions
compositions containing
use therefor
Prior art date
Application number
BRPI0312649A
Other languages
English (en)
Inventor
A Townsend Craig
P Kuhadja Francis
Thupari Jagan
M Mcfadden Jill
M Medghalchi Susan
Original Assignee
Fasgen Llc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fasgen Llc, Univ Johns Hopkins filed Critical Fasgen Llc
Publication of BRPI0312649A2 publication Critical patent/BRPI0312649A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0312649A 2002-07-09 2003-07-09 compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos. BRPI0312649A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39458502P 2002-07-09 2002-07-09
PCT/US2003/021700 WO2004005277A1 (en) 2002-07-09 2003-07-09 Novel compunds, pharmaceutical compositions containing same, and methods of use for same

Publications (1)

Publication Number Publication Date
BRPI0312649A2 true BRPI0312649A2 (pt) 2017-05-16

Family

ID=30115739

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312649A BRPI0312649A2 (pt) 2002-07-09 2003-07-09 compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.

Country Status (13)

Country Link
US (2) US7649012B2 (pt)
EP (3) EP2386551A1 (pt)
JP (3) JP2005533835A (pt)
KR (1) KR101087559B1 (pt)
CN (2) CN100513404C (pt)
AU (1) AU2003265267B2 (pt)
BR (1) BRPI0312649A2 (pt)
CA (2) CA2767092C (pt)
EA (1) EA013371B1 (pt)
IL (2) IL166108A0 (pt)
MX (1) MXPA05000365A (pt)
SG (1) SG169236A1 (pt)
WO (1) WO2004005277A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471906A4 (en) 2002-02-08 2006-02-01 Univ Johns Hopkins Med STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT
JP4493494B2 (ja) * 2002-07-09 2010-06-30 ファスゲン，インク． ヒトおよび動物における微生物感染症の治療方法
EP2386551A1 (en) * 2002-07-09 2011-11-16 Fasgen Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same
CN101022792A (zh) * 2004-05-26 2007-08-22 法斯根有限责任公司 新化合物、包含该化合物的药物组合物及该化合物的应用方法
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
JP2010509335A (ja) * 2006-11-08 2010-03-25 ファスゲン エルエルシー 新規の化合物、それを含有する医薬組成物、及びその使用方法
WO2008059214A1 (en) * 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors
WO2009149066A1 (en) * 2008-06-02 2009-12-10 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
US9149445B2 (en) 2009-07-27 2015-10-06 The Trustees Of Princeton University Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012135027A2 (en) * 2011-03-25 2012-10-04 The Research Foundation Of State University Of New York Thiolactone antibiotics
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013280980B2 (en) 2012-06-25 2017-10-19 Thomas Jefferson University Compositions and methods for treating cancer with aberrant lipogenic signaling
JP6285442B2 (ja) * 2012-09-07 2018-02-28 ヤンセン ファーマシューティカ エヌ．ベー． がん治療用の脂肪酸合成酵素（ｆａｓｎ）阻害剤として有用なイミダゾリン−５−オン誘導体
SG10201707409PA (en) 2013-03-13 2017-10-30 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
WO2016079317A1 (en) 2014-11-20 2016-05-26 Vib Vzw Means and methods for treatment of early-onset parkinson's disease
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN114480521B (zh) * 2020-11-13 2024-07-26 中国科学院青岛生物能源与过程研究所 一种三氮菌素c的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496187A (en) * 1967-03-20 1970-02-17 American Home Prod N-(heterocyclyl)aconamides
US3472878A (en) * 1969-01-27 1969-10-14 American Home Prod N-(hydroxyaryl)aconamides
JPS5859920A (ja) * 1981-10-05 1983-04-09 Chugai Pharmaceut Co Ltd 生体防禦能賦活剤
US4565699A (en) * 1983-07-18 1986-01-21 The Upjohn Company Composition of matter and process
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
CH667655A5 (de) * 1986-09-24 1988-10-31 Lonza Ag Verfahren zur herstellung von 4-alkoxy-2(5h)-thiophenonen.
US4753871A (en) * 1986-12-12 1988-06-28 Eastman Kodak Company Cyan dye-forming couplers and photographic materials containing same
AU1044088A (en) * 1986-12-17 1988-07-15 Nippon Soda Co., Ltd. Heterocyclic compounds having triketo skeleton
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5759791A (en) * 1989-01-17 1998-06-02 The Johns Hopkins University Cancer related antigen
US5679801A (en) * 1991-04-12 1997-10-21 American Home Products Corporation Tetronic and thiotetronic acid derivatives as phospholipase A2 inhibitors
US5614551A (en) 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
CN1131209C (zh) * 1995-05-09 2003-12-17 拜尔公司 可用作杀虫剂和除草剂的烷基－二卤代苯基取代的酮烯醇
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
JPH10212284A (ja) * 1996-11-27 1998-08-11 Sagami Chem Res Center テトロン酸−３−カルボン酸誘導体、その製造方法、製造中間体、抗がん剤、及び蛋白脱リン酸化酵素阻害剤
US6391912B1 (en) * 1996-12-12 2002-05-21 Bayer Aktiengesellschaft Substituted phenylketoenols
CO4970714A1 (es) * 1997-09-05 2000-11-07 Boehringer Mannheim Gmbh Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h) tiofenonas como agentes antitumorales
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
IT1315267B1 (it) * 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
GB0000131D0 (en) * 2000-01-06 2000-02-23 Univ Cardiff Thiolactomycin analogues,compositions containing the same and uses thereof
US6376682B1 (en) * 2000-02-01 2002-04-23 Takama System, Ltd. Compound with α-glucosidase inhibiting action and method for producing the same
MY134040A (en) 2001-05-02 2007-11-30 Univ New York Inhibition of pigmentation by inhibition of fatty acid synthase
EP1471906A4 (en) * 2002-02-08 2006-02-01 Univ Johns Hopkins Med STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT
EP2386551A1 (en) * 2002-07-09 2011-11-16 Fasgen Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same
JP4493494B2 (ja) 2002-07-09 2010-06-30 ファスゲン，インク． ヒトおよび動物における微生物感染症の治療方法
US9690894B1 (en) 2015-11-02 2017-06-27 Altera Corporation Safety features for high level design

Also Published As

Publication number Publication date
CA2767092C (en) 2013-10-15
JP2011037881A (ja) 2011-02-24
MXPA05000365A (es) 2005-09-20
HK1083835A1 (zh) 2006-07-14
IL166108A0 (en) 2006-01-15
SG169236A1 (en) 2011-03-30
US20060247302A1 (en) 2006-11-02
EA013371B1 (ru) 2010-04-30
CA2767092A1 (en) 2004-01-15
CN100513404C (zh) 2009-07-15
CA2491802C (en) 2012-04-10
JP2005533835A (ja) 2005-11-10
KR20060002007A (ko) 2006-01-06
CN1675192A (zh) 2005-09-28
EP1539730A4 (en) 2007-03-28
WO2004005277A1 (en) 2004-01-15
KR101087559B1 (ko) 2011-11-29
CN101602756B (zh) 2014-11-12
JP2013189464A (ja) 2013-09-26
US7649012B2 (en) 2010-01-19
CN101602756A (zh) 2009-12-16
EP2386551A1 (en) 2011-11-16
EP1539730A1 (en) 2005-06-15
EP2386550A1 (en) 2011-11-16
IL190218A0 (en) 2008-11-03
CA2491802A1 (en) 2004-01-15
EA200500178A1 (ru) 2006-02-24
US20100120901A1 (en) 2010-05-13
AU2003265267B2 (en) 2010-03-11
AU2003265267A1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
BR0300500B1 (pt) composiÇço poliolefÍnica, processo para estabilizaÇço de uma poliolefina e uso de uma mistura.
BRPI0407755B1 (pt) composiÇço catalÍtica, sua preparaÇço e uso
DK1399444T3 (da) Nye heterocycliske forbindelser, fremgangsmåde til fremstilling af samme samt anvendelse deraf som lægemidler, især som antibakterielle midler
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0009956B8 (pt) Composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
UY28348A1 (es) Compuestos novedosos
BR0214263B1 (pt) processos para a preparaÇço de uma composiÇço para o tratamento dos cabelos.
NO20044256L (no) Makrosykliske forbindelser som kan anvendes som farmasoytika
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
BR0113494B1 (pt) processo para a preparaÇço de uma formulaÇço sàlida herbicida, e, uso de uma formulaÇço sàlida herbicida.
IS6986A (is) Lyfjasamsetning í vökvaformi
DK1500654T3 (da) Benzoxazinonderivater, fremstilling deraf og anvendelse deraf som lægemidler
EP1539122A4 (en) PHARMACEUTICAL AQUEOUS 2,6-DIISOPROPYLPHENOL COMPOSITIONS
PT1560826E (pt) Compostos piridopirimidinona, seus processos de preparacao e composicoes farmaceuticas que os contem
HUS1500006I1 (hu) Benzotiazol-származék vegyületek, kompozíciók és alkalmazások
BRPI0312413A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos
CL2004001678A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica; y uso de los compuestos como agentes bacterianos.
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.

Legal Events

Date Code Title Description
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]